Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

[Sarcoidosis-lymphoma syndrome showing abnormal FDG uptake in lymph nodes and muscles upon post-chemotherapy PET/CT imaging].

Nakano K, Ito Y, Takagi F, Uchiyama S, Yoda A, Sakamoto N, Takaba M, Adachi M, Takemura T, Nagata Y, Ono T.

Rinsho Ketsueki. 2019;60(4):302-307. doi: 10.11406/rinketsu.60.302. Japanese.

PMID:
31068560
2.

[What do we know about diabetic retinopathy at the Sourô Sanou university medical center in Bobo-Dioulasso (CHUSS)?]

Diallo JW, Dolo M, Sanou J, Yoda A, Ahnoux-Zabsonré A, Méda N.

J Fr Ophtalmol. 2019 Apr;42(4):361-367. doi: 10.1016/j.jfo.2018.11.002. Epub 2019 Mar 23. French.

PMID:
30910329
3.

A Rare Case of Cryopyrin-associated Periodic Syndrome in an Elderly Woman with NLRP3 and MEFV Mutations.

Nakamichi S, Origuchi T, Fukui S, Yoda A, Matsubara H, Nagaura Y, Nishikomori R, Abe K, Migita K, Sakamoto N, Kawakami A, Ozono Y, Maeda T.

Intern Med. 2019 Apr 1;58(7):1017-1022. doi: 10.2169/internalmedicine.1401-18. Epub 2018 Dec 18.

4.

Molecular pathogenesis of disease progression in MLL-rearranged AML.

Kotani S, Yoda A, Kon A, Kataoka K, Ochi Y, Shiozawa Y, Hirsch C, Takeda J, Ueno H, Yoshizato T, Yoshida K, Nakagawa MM, Nannya Y, Kakiuchi N, Yamauchi T, Aoki K, Shiraishi Y, Miyano S, Maeda T, Maciejewski JP, Takaori-Kondo A, Ogawa S, Makishima H.

Leukemia. 2019 Mar;33(3):612-624. doi: 10.1038/s41375-018-0253-3. Epub 2018 Sep 12.

5.

Conversion of carlactone to carlactonoic acid is a conserved function of MAX1 homologs in strigolactone biosynthesis.

Yoneyama K, Mori N, Sato T, Yoda A, Xie X, Okamoto M, Iwanaga M, Ohnishi T, Nishiwaki H, Asami T, Yokota T, Akiyama K, Yoneyama K, Nomura T.

New Phytol. 2018 Jun;218(4):1522-1533. doi: 10.1111/nph.15055. Epub 2018 Feb 26.

6.

Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E.

Joyce CE, Yanez AG, Mori A, Yoda A, Carroll JS, Novina CD.

Cancer Res. 2017 Feb 1;77(3):613-622. doi: 10.1158/0008-5472.CAN-16-1298. Epub 2016 Nov 22. Erratum in: Cancer Res. 2017 Mar 15;77(6):1505.

7.

Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias.

Dunford A, Weinstock DM, Savova V, Schumacher SE, Cleary JP, Yoda A, Sullivan TJ, Hess JM, Gimelbrant AA, Beroukhim R, Lawrence MS, Getz G, Lane AA.

Nat Genet. 2017 Jan;49(1):10-16. doi: 10.1038/ng.3726. Epub 2016 Nov 21.

8.

The Mediator Kinase Module Restrains Epidermal Growth Factor Receptor Signaling and Represses Vulval Cell Fate Specification in Caenorhabditis elegans.

Grants JM, Ying LT, Yoda A, You CC, Okano H, Sawa H, Taubert S.

Genetics. 2016 Feb;202(2):583-99. doi: 10.1534/genetics.115.180265. Epub 2015 Dec 29.

9.

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, Christie AL, Liu H, Christodoulou A, van Bodegom D, van der Zwet J, Layer JV, Tivey T, Lane AA, Ryan JA, Ng SY, DeAngelo DJ, Stone RM, Steensma D, Wadleigh M, Harris M, Mandon E, Ebel N, Andraos R, Romanet V, Dölemeyer A, Sterker D, Zender M, Rodig SJ, Murakami M, Hofmann F, Kuo F, Eck MJ, Silverman LB, Sallan SE, Letai A, Baffert F, Vangrevelinghe E, Radimerski T, Gaul C, Weinstock DM.

Cancer Cell. 2015 Jul 13;28(1):29-41. doi: 10.1016/j.ccell.2015.06.005.

10.

Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.

Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA.

Nat Med. 2015 Jan;21(1):71-5. doi: 10.1038/nm.3751. Epub 2014 Dec 8.

11.

Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia.

Mansour MR, Reed C, Eisenberg AR, Tseng JC, Twizere JC, Daakour S, Yoda A, Rodig SJ, Tal N, Shochat C, Berezovskaya A, DeAngelo DJ, Sallan SE, Weinstock DM, Izraeli S, Kung AL, Kentsis A, Look AT.

Br J Haematol. 2015 Jan;168(2):230-8. doi: 10.1111/bjh.13115. Epub 2014 Sep 26.

12.

Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.

Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, van Bodegom D, Day TA, Wu SC, Liu H, Yoda A, Alexe G, Schinzel AC, Sullivan TJ, Malinge S, Taylor JE, Stegmaier K, Jaffe JD, Bustin M, te Kronnie G, Izraeli S, Harris MH, Stevenson KE, Neuberg D, Silverman LB, Sallan SE, Bradner JE, Hahn WC, Crispino JD, Pellman D, Weinstock DM.

Nat Genet. 2014 Jun;46(6):618-23. doi: 10.1038/ng.2949. Epub 2014 Apr 20.

13.

TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling.

Zhong J, Sharma J, Raju R, Palapetta SM, Prasad TS, Huang TC, Yoda A, Tyner JW, van Bodegom D, Weinstock DM, Ziegler SF, Pandey A.

Database (Oxford). 2014 Feb 25;2014:bau007. doi: 10.1093/database/bau007. Print 2014.

14.

Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia.

Lane AA, Odejide O, Kopp N, Kim S, Yoda A, Erlich R, Wagle N, Abel GA, Rodig SJ, Antin JH, Weinstock DM.

Leukemia. 2013 Apr;27(4):968-71. doi: 10.1038/leu.2013.30. Epub 2013 Feb 1. No abstract available.

15.

Next-generation cDNA screening for oncogene and resistance phenotypes.

Shindoh N, Yoda A, Yoda Y, Sullivan TJ, Weigert O, Lane AA, Kopp N, Bird L, Rodig SJ, Fox EA, Weinstock DM.

PLoS One. 2012;7(11):e49201. doi: 10.1371/journal.pone.0049201. Epub 2012 Nov 7.

16.

Familial Mediterranean fever with onset at 66 years of age.

Inoue K, Torii K, Yoda A, Kadota K, Nakamichi S, Obata Y, Nishino T, Migita K, Kawakami A, Ozono Y.

Intern Med. 2012;51(18):2649-53. Epub 2012 Sep 15.

17.

Eosinophilic enteritis: efficiency of the 13C-acetate breath test for assessing the disease activity.

Yoda A, Takeshima F, Kadota K, Inoue K, Nakamichi S, Hayashi T, Nakao K, Oozono Y.

Intern Med. 2012;51(18):2551-4. Epub 2012 Sep 15.

18.

Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2.

van Bodegom D, Zhong J, Kopp N, Dutta C, Kim MS, Bird L, Weigert O, Tyner J, Pandey A, Yoda A, Weinstock DM.

Blood. 2012 Oct 4;120(14):2853-63. doi: 10.1182/blood-2012-02-413252. Epub 2012 Aug 20.

19.

BCL2 suppresses PARP1 function and nonapoptotic cell death.

Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown JR, Shapiro GI, Letai A, Weinstock DM.

Cancer Res. 2012 Aug 15;72(16):4193-203. doi: 10.1158/0008-5472.CAN-11-4204. Epub 2012 Jun 11.

20.

Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.

Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, Bahar AY, Chapuy B, Kutok JL, Longtine JA, Kuo FC, Haley T, Salois M, Sullivan TJ, Fisher DC, Fox EA, Rodig SJ, Antin JH, Weinstock DM.

Cancer Discov. 2012 Jan;2(1):47-55. doi: 10.1158/2159-8290.CD-11-0208. Epub 2011 Dec 12.

21.

TSLP signaling network revealed by SILAC-based phosphoproteomics.

Zhong J, Kim MS, Chaerkady R, Wu X, Huang TC, Getnet D, Mitchell CJ, Palapetta SM, Sharma J, O'Meally RN, Cole RN, Yoda A, Moritz A, Loriaux MM, Rush J, Weinstock DM, Tyner JW, Pandey A.

Mol Cell Proteomics. 2012 Jun;11(6):M112.017764. doi: 10.1074/mcp.M112.017764. Epub 2012 Feb 16.

22.

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.

Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeown M, Paranal RM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A, Régnier CH, Erdmann D, Hofmann F, Eck MJ, Sallan SE, Levine RL, Kung AL, Baffert F, Radimerski T, Weinstock DM.

J Exp Med. 2012 Feb 13;209(2):259-73. doi: 10.1084/jem.20111694. Epub 2012 Jan 23.

23.

Early effects of smoking cessation and weight gain on plasma adiponectin levels and insulin resistance.

Inoue K, Takeshima F, Kadota K, Yoda A, Tatsuta Y, Nagaura Y, Yoshioka S, Nakamichi S, Nakao K, Ozono Y.

Intern Med. 2011;50(7):707-12. Epub 2011 Apr 1.

24.

t(X;14)(p22;q32)/t(Y;14)(p11;q32) CRLF2-IGH translocations from human B-lineage ALLs involve CpG-type breaks at CRLF2, but CRLF2/P2RY8 intrachromosomal deletions do not.

Tsai AG, Yoda A, Weinstock DM, Lieber MR.

Blood. 2010 Sep 16;116(11):1993-4. doi: 10.1182/blood-2010-05-286492. No abstract available.

25.

Novel ELISA using intracellularly biotinylated antigen for detection of antibody following DNA immunization.

Kimura R, Yoda A, Hayashizaki Y, Chiba J.

Jpn J Infect Dis. 2010 Jan;63(1):41-8.

26.

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.

Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):252-7. doi: 10.1073/pnas.0911726107. Epub 2009 Dec 15.

27.

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.

Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, Zeligson S, Cario G, Stanulla M, Strehl S, Russell LJ, Harrison CJ, Bornhauser B, Yoda A, Rechavi G, Bercovich D, Borkhardt A, Kempski H, te Kronnie G, Bourquin JP, Domany E, Izraeli S.

Blood. 2010 Feb 4;115(5):1006-17. doi: 10.1182/blood-2009-08-235408. Epub 2009 Nov 24.

28.

[Three cases of isocyanate-induced hypersensitivity pneumonitis with different HRCT findings].

Hara S, Yamamoto K, Yoda A, Nakayama S, Sakamoto N, Ishimatsu Y, Mukae H, Kohno S.

Nihon Kokyuki Gakkai Zasshi. 2009 Sep;47(9):839-43. Japanese.

PMID:
19827591
29.

[Two cases of pleomorphic carcinoma with severe systemic inflammation].

Yoda A, Nakayama S, Abe K, Inoue K, Nakamura Y, Tagawa T, Hayashi T, Mukae H, Kohno S, Ozono Y.

Nihon Kokyuki Gakkai Zasshi. 2009 Aug;47(8):751-7. Review. Japanese.

PMID:
19764522
30.

Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.

Yoda A, Toyoshima K, Watanabe Y, Onishi N, Hazaka Y, Tsukuda Y, Tsukada J, Kondo T, Tanaka Y, Minami Y.

J Biol Chem. 2008 Jul 4;283(27):18969-79. doi: 10.1074/jbc.M800560200. Epub 2008 May 15.

31.

Chk2 kinase is required for methylglyoxal-induced G2/M cell-cycle checkpoint arrest: implication of cell-cycle checkpoint regulation in diabetic oxidative stress signaling.

Kani S, Nakayama E, Yoda A, Onishi N, Sougawa N, Hazaka Y, Umeda T, Takeda K, Ichijo H, Hamada Y, Minami Y.

Genes Cells. 2007 Aug;12(8):919-28.

32.

Effect of curing method and storage condition on fluoride ion release from a fluoride-releasing resin cement.

Yoda A, Nikaido T, Ikeda M, Sonoda H, Foxton RM, Tagami J.

Dent Mater J. 2006 Jun;25(2):261-6.

33.

The role of X/Y linker region and N-terminal EF-hand domain in nuclear translocation and Ca2+ oscillation-inducing activities of phospholipase Czeta, a mammalian egg-activating factor.

Kuroda K, Ito M, Shikano T, Awaji T, Yoda A, Takeuchi H, Kinoshita K, Miyazaki S.

J Biol Chem. 2006 Sep 22;281(38):27794-805. Epub 2006 Jul 19.

34.

[Relationship between abnormalities of genes involved in DNA damage responses and malignant tumors/autoimmune diseases].

Yoo SK, Onishi N, Kato N, Yoda A, Minami Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2006 Jun;29(3):136-47. Review. Japanese.

35.

Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1.

Yoda A, Xu XZ, Onishi N, Toyoshima K, Fujimoto H, Kato N, Oishi I, Kondo T, Minami Y.

J Biol Chem. 2006 Aug 25;281(34):24847-62. Epub 2006 Jun 23.

36.

Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase.

Fujimoto H, Onishi N, Kato N, Takekawa M, Xu XZ, Kosugi A, Kondo T, Imamura M, Oishi I, Yoda A, Minami Y.

Cell Death Differ. 2006 Jul;13(7):1170-80. Epub 2005 Nov 25.

37.
38.

The receptor tyrosine kinase Ror2 associates with and is activated by casein kinase Iepsilon.

Kani S, Oishi I, Yamamoto H, Yoda A, Suzuki H, Nomachi A, Iozumi K, Nishita M, Kikuchi A, Takumi T, Minami Y.

J Biol Chem. 2004 Nov 26;279(48):50102-9. Epub 2004 Sep 15.

39.

Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin's lymphoma cell lines.

Kato N, Fujimoto H, Yoda A, Oishi I, Matsumura N, Kondo T, Tsukada J, Tanaka Y, Imamura M, Minami Y.

Cell Death Differ. 2004 Dec;11 Suppl 2:S153-61.

40.

Oda5p, a novel axonemal protein required for assembly of the outer dynein arm and an associated adenylate kinase.

Wirschell M, Pazour G, Yoda A, Hirono M, Kamiya R, Witman GB.

Mol Biol Cell. 2004 Jun;15(6):2729-41. Epub 2004 Apr 2.

41.

Ca2+ oscillation-inducing phospholipase C zeta expressed in mouse eggs is accumulated to the pronucleus during egg activation.

Yoda A, Oda S, Shikano T, Kouchi Z, Awaji T, Shirakawa H, Kinoshita K, Miyazaki S.

Dev Biol. 2004 Apr 15;268(2):245-57.

42.
43.

Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases.

Nomi M, Oishi I, Kani S, Suzuki H, Matsuda T, Yoda A, Kitamura M, Itoh K, Takeuchi S, Takeda K, Akira S, Ikeya M, Takada S, Minami Y.

Mol Cell Biol. 2001 Dec;21(24):8329-35.

44.
45.

[Improvement in the regimen for combined CDDP and CPT-11 chemotherapy].

Shimizu A, Sugitoh Y, Hasegawa A, Okubo K, Fujihara T, Ishikawa T, Suzuki N, Yoda A, Narabayashi A, Takahashi J, Notake Y.

Gan To Kagaku Ryoho. 2000 Oct;27(12):1807-11. Japanese.

PMID:
11086417
46.

Effect of lactoferrin on lipopolysaccharide (LPS) induced preterm delivery in mice.

Mitsuhashi Y, Otsuki K, Yoda A, Shimizu Y, Saito H, Yanaihara T.

Acta Obstet Gynecol Scand. 2000 May;79(5):355-8.

PMID:
10830761
47.

[Significance and effects of intraperitoneal cisplatin administration for ovarian cancer].

Shimizu A, Ookubo K, Hasegawa J, Endoh T, Fujiwara O, Yoda A, Okuyama D, Narabayashi A, Kimura T, Takahashi J, Notake Y.

Gan To Kagaku Ryoho. 1999 Oct;26(12):1801-5. Japanese.

PMID:
10560398
48.

Amniotic fluid lactoferrin in intrauterine infection.

Otsuki K, Yoda A, Saito H, Mitsuhashi Y, Toma Y, Shimizu Y, Yanaihara T.

Placenta. 1999 Mar-Apr;20(2-3):175-9.

PMID:
10195738
49.

The human Musashi homolog 1 (MSI1) gene encoding the homologue of Musashi/Nrp-1, a neural RNA-binding protein putatively expressed in CNS stem cells and neural progenitor cells.

Good P, Yoda A, Sakakibara S, Yamamoto A, Imai T, Sawa H, Ikeuchi T, Tsuji S, Satoh H, Okano H.

Genomics. 1998 Sep 15;52(3):382-4. No abstract available.

PMID:
9790759
50.

Lactoferrin and interleukin-6 interaction in amniotic infection.

Otsuki K, Yoda A, Toma Y, Shimizu Y, Saito H, Yanaihara T.

Adv Exp Med Biol. 1998;443:267-71.

PMID:
9781369

Supplemental Content

Support Center